A multicentre, multinational study of clinical characteristics and prognosis of hepatocellular carcinoma

被引:4
作者
Dirican, Ahmet [1 ]
Uncu, Dogan [2 ]
Sekacheva, Marina [3 ]
Artac, Mehmet [4 ]
Aladashvil, Archil [5 ]
Erdogan, Atike [6 ]
Kaplan, Muhammet [7 ]
Alacacioglu, Ahmet [8 ]
Boukovinas, Ioannis [9 ]
Turhal, Nazim [10 ]
机构
[1] Izmir Univ Econ, Medicalpark Hosp, Dept Med Oncol, Izmir, Turkiye
[2] Hlth Sci Univ, Ankara Numune Educ & Res Hosp, Dept Med Oncol, Ankara, Turkiye
[3] Sechenov First Moscow State Med Univ, World Class Res Ctr & Personalized Healthcare, Moscow, Russia
[4] Necmettin Erbakan Univ, Meram Med Fac, Dept Med Oncol, Konya, Turkiye
[5] Tbilisi State Med Univ, Natl Canc Ctr, Canc Res Unit & Oncol Surg, Tbilisi, Georgia
[6] Manisa Celal Bayar Univ, Med Fac, Dept Med Oncol, Manisa, Turkiye
[7] Dicle Univ, Med Med Fac, Dept Oncol, Diyarbakir, Turkiye
[8] Izmir katip Celebi Univ, Med Fac, Dept Med Oncol, Izmir, Turkiye
[9] Bioclin Thessaloniki, Med Oncol Unit, Thessaloniki, Greece
[10] Anatolia Med Ctr, Dept Med Oncol, Istanbul, Turkiye
关键词
hepatocellular carcinoma; prognosis; neutrophil to lymphocyte ratio; Turkiye; Russia; Georgia; Greece; MONOCYTE COUNTS; UNITED-STATES; CANCER; NEUTROPHIL; SORAFENIB; CIRRHOSIS; FEATURES;
D O I
10.26719/emhj.23.087
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Hepatocellular carcinoma (HCC) is a significant health problem, and the associated mortality rate is increasing.Aim: We aimed to determine the clinical characteristics and prognosis for HCC in member countries of the OncoBridge Study Group. Methods: We recruited 630 patients diagnosed with HCC between 2013 and 2019 from 4 countries (Turkiye, Russia, Georgia, and Greece). Univariate and multivariate analyses were conducted to investigate clinical and laboratory prognostic factors. Receiver operating characteristic (ROC) analysis was used to determine the prognostic value of the neutrophil to lymphocyte ratio (NLR) and alpha-fetoprotein (AFP) value.Results: The 3 most common etiological factors were hepatitis B infection (39.7%), hepatitis C virus infection (17.0%) and non-alcoholic fatty liver disease (9.0%). Median overall survival for the whole group was 25 [95% confidence interval (CI): 15.7-34.2] months. Cut-off values for AFP and NLR were accepted as 200 ng/mL and 3.45, respectively. The area under the ROC curve values for AFP, NLR and NLR+AFP were 0.625 (95% CI: 0.547-0.704), 0.589 (95% CI: 0.512-0.667) and 0.657 (95% CI: 0.583-0.731). From the multivariate analysis, advanced tumour size, lymph node involvement and metastasis (TNM) stage, presence of cirrhosis, high AFP, and high NLR values were associated with poor survival.Conclusion: AFP, NLR, advanced TNM, and presence of cirrhosis may predict prognosis in patients with HCC. Studies involving more countries are needed to corroborate these findings.
引用
收藏
页码:462 / 473
页数:12
相关论文
共 44 条
[1]  
Abdel-Wahab M, 2007, HEPATO-GASTROENTEROL, V54, P157
[2]   Phase II study of sorafenib in patients with advanced hepatocellular carcinoma [J].
Abou-Alfa, Ghassan K. ;
Schwartz, Lawrence ;
Ricci, Sergio ;
Amadori, Dino ;
Santoro, Armando ;
Figer, Arie ;
De Greve, Jacques ;
Douillard, Jean-Yves ;
Lathia, Chetan ;
Schwartz, Brian ;
Taylor, Ian ;
Moscovici, Marius ;
Saltz, Leonard B. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (26) :4293-4300
[3]   Relative Importance of Hepatitis B and C Viruses in Hepatocellular Carcinoma in EMRO Countries and the Middle East: A Systematic Review [J].
Alavian, Seyed Moayed ;
Haghbin, Hossein .
HEPATITIS MONTHLY, 2016, 16 (03)
[4]   Molecular viral oncology of hepatocellular carcinoma [J].
Block, TM ;
Mehta, AS ;
Fimmel, CJ ;
Jordan, R .
ONCOGENE, 2003, 22 (33) :5093-5107
[5]   Hepatocellular Carcinoma Survival by Etiology: A SEER-Medicare Database Analysis [J].
Brar, Gagandeep ;
Greten, Tim F. ;
Graubard, Barry, I ;
McNeel, Timothy S. ;
Petrick, Jessica L. ;
McGlynn, Katherine A. ;
Altekruse, Sean F. .
HEPATOLOGY COMMUNICATIONS, 2020, 4 (10) :1541-1551
[6]   Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial [J].
Cheng, Ann-Lii ;
Kang, Yoon-Koo ;
Chen, Zhendong ;
Tsao, Chao-Jung ;
Qin, Shukui ;
Kim, Jun Suk ;
Luo, Rongcheng ;
Feng, Jifeng ;
Ye, Shenglong ;
Yang, Tsai-Sheng ;
Xu, Jianming ;
Sun, Yan ;
Liang, Houjie ;
Liu, Jiwei ;
Wang, Jiejun ;
Tak, Won Young ;
Pan, Hongming ;
Burock, Karin ;
Zou, Jessie ;
Voliotis, Dimitris ;
Guan, Zhongzhen .
LANCET ONCOLOGY, 2009, 10 (01) :25-34
[7]   Multiplication of neutrophil and monocyte counts (MNM) as an easily obtainable tumour marker for cervical cancer [J].
Cho, Hanbyoul ;
Kim, Jae-Hoon .
BIOMARKERS, 2009, 14 (03) :161-170
[8]   Development of a New Nomogram Including Neutrophil-to-Lymphocyte Ratio to Predict Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization [J].
Chon, Young Eun ;
Park, Hana ;
Hyun, Hye Kyung ;
Ha, Yeonjung ;
Kim, Mi Na ;
Kim, Beom Kyung ;
Lee, Joo Ho ;
Kim, Seung Up ;
Kim, Do Young ;
Ahn, Sang Hoon ;
Hwang, Seong Gyu ;
Han, Kwang-Hyub ;
Rim, Kyu Sung ;
Park, Jun Yong .
CANCERS, 2019, 11 (04)
[9]   Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies [J].
Cupp, Meghan A. ;
Cariolou, Margarita ;
Tzoulaki, Ioanna ;
Aune, Dagfinn ;
Evangelou, Evangelos ;
Berlanga-Taylor, Antonio J. .
BMC MEDICINE, 2020, 18 (01)
[10]  
European Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019